This article is for informational purposes only and does not constitute medical advice. All safety information discussed below reflects publicly available clinical data and FDA labeling as of April 2026. Consult a qualified healthcare professional before starting, stopping, or modifying any medication.
GLP-1 Medication Safety in 2026: Side Effects, Contraindications, Drug Interactions, and the Regulatory Questions Every Patient Should Ask Before Starting
The conversation around GLP-1 medications has been dominated by weight loss results and cost comparisons, and for understandable reasons — those are the factors that drive most purchasing decisions. But if you're seriously considering starting semaglutide, tirzepatide, or any GLP-1 receptor agonist through a telehealth platform, the safety profile deserves at least as much attention as the pricing page. These are prescription medications with real pharmacological effects, documented side effects, and specific populations for whom they're not appropriate. Here's what the clinical evidence says.
Common Side Effects During GLP-1 Titration
Gastrointestinal symptoms are the most frequently reported side effects of GLP-1 medications, and they're directly related to the mechanism of action. By slowing gastric emptying and altering appetite signaling, these drugs commonly produce nausea, particularly during the initial titration phase and after dose increases. In clinical trials of semaglutide 2.4 mg (the Wegovy dose), approximately 44% of participants reported nausea, though the majority described it as mild to moderate and time-limited.
Other commonly reported gastrointestinal effects include diarrhea, constipation, abdominal pain, and vomiting. These symptoms are most pronounced at the beginning of treatment and tend to diminish as the body adjusts over two to four weeks at each dose level. This is exactly why proper titration — starting at low doses and increasing gradually — matters so much. Platforms that rush patients to therapeutic doses increase the likelihood of intolerable GI effects that cause discontinuation.
Some compounded GLP-1 formulations, including those prescribed through Direct Meds, include ondansetron (the anti-nausea medication sold as Zofran) alongside the GLP-1 active ingredient. This is a practical approach to managing the most common barrier to treatment adherence, though patients should be aware that ondansetron carries its own side effect profile and drug interaction considerations.
Absolute Contraindications: Who Should Not Take GLP-1 Medications
The most critical contraindication for all GLP-1 receptor agonists relates to thyroid cancer risk. In animal studies, semaglutide and tirzepatide have been associated with thyroid C-cell tumors. While the relevance to humans hasn't been conclusively established, the medications carry a black box warning — the FDA's most serious labeling category — against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
This screening should be part of every intake evaluation, regardless of the platform. If a telehealth provider approves a GLP-1 prescription without asking about thyroid cancer history, that's a meaningful red flag about their clinical thoroughness.
Other populations for whom GLP-1 medications require heightened caution or may be contraindicated include patients with a history of pancreatitis (GLP-1 medications have been associated with reports of acute pancreatitis, though a causal relationship hasn't been definitively established), patients with gastroparesis or severe gastrointestinal disease (slowed gastric emptying can exacerbate these conditions), pregnant or breastfeeding women (GLP-1 medications should be discontinued at least two months before planned conception, per current labeling), and patients with a history of suicidal ideation (the FDA is evaluating reports of suicidal thoughts in patients taking GLP-1 medications, though a causal link has not been confirmed as of April 2026).
Drug Interactions Worth Discussing With Your Provider
Because GLP-1 medications slow gastric emptying, they can affect the absorption of other oral medications you take. This is particularly relevant for medications with narrow therapeutic windows — drugs where small changes in absorption timing can meaningfully affect efficacy or safety.
Oral contraceptives are one commonly cited example. Slowed absorption could theoretically reduce the efficacy of birth control pills, though clinical studies haven't shown a clinically significant effect for most formulations. Nonetheless, patients using oral contraceptives should discuss this with their prescriber.
Insulin and sulfonylureas present a more significant interaction concern. GLP-1 medications improve insulin sensitivity and lower blood sugar. When combined with insulin or medications that stimulate insulin secretion, the risk of hypoglycemia increases. Patients with type 2 diabetes who are already on glucose-lowering medications need careful dose adjustment when starting GLP-1 therapy — this isn't a do-it-yourself situation.
Other medications that warrant a conversation include blood thinners like warfarin (absorption timing changes), thyroid medications like levothyroxine (should be taken on an empty stomach, and GLP-1's gastric effects could alter absorption), and any medication that's dosed precisely based on timing relative to food intake.
For patients managing multiple prescriptions, the asynchronous intake model used by many telehealth platforms — where a provider reviews a written form rather than conducting a live clinical interview — may not provide adequate depth to identify these interaction risks. This is one reason having a primary care provider who knows your full medication profile is valuable even if you're accessing GLP-1 therapy through a separate telehealth channel. Our clinical evaluation of Direct Meds discusses how the platform's consultation model handles these considerations.
Compounding-Specific Safety Considerations
When your GLP-1 medication comes from a compounding pharmacy rather than a pharmaceutical manufacturer, additional safety considerations apply. Compounded medications haven't undergone the same premarket review process as FDA-approved drugs. The active ingredient may be the same, but the formulation, excipients, concentration accuracy, and sterility protocols can differ.
The best peptides and GLP-1 formulations from compounding pharmacies come from facilities that maintain rigorous quality controls. Patients should look for pharmacies that are licensed and inspected by their state board of pharmacy, ideally PCAB-accredited, producing medications with documented potency testing, and operating under proper sterility protocols for injectable formulations. The term best oral peptides is sometimes used in marketing to describe sublingual GLP-1 drops and other non-injectable formats, but patients should apply the same quality scrutiny to oral compounded formulations as to injectables.
One specific concern that emerged in 2025 was semaglutide acetate — a chemically distinct salt form of semaglutide not used in any FDA-approved product and not validated in human clinical trials. Reputable compounding pharmacies use validated forms of semaglutide. If your compounding pharmacy can't confirm which form they're using, that's a reason to ask questions before proceeding.
The 2026 Regulatory Environment: What Patients Need to Understand
The regulatory environment for compounded GLP-1 medications has changed substantially since early 2025 and continues to evolve. Both semaglutide and tirzepatide have been removed from the FDA's drug shortage list, which was the primary statutory basis for large-scale compounding of these medications. Federal litigation has created a patchwork of enforcement outcomes, and the FDA's posture toward compounders has become increasingly restrictive throughout early 2026.
For patients, the practical implication is this: compounded semaglutide and tirzepatide remain available through 503A pharmacies and many 503B facilities as of April 2026, but the long-term availability isn't guaranteed. If you start a compounded GLP-1 program today, it's worth having a conversation with your provider about what happens if compounded formulations become unavailable — including whether transitioning to a brand-name product is financially and clinically feasible for your situation.
This regulatory context affects every telehealth platform offering compounded GLP-1 medications, not just any single company. For a comparison of how different platforms are positioned within this environment, see our GLP-1 telehealth platform comparison covering Direct Meds, Hims, Ro, Henry Meds, and MEDVi.
A Safety-First Framework for Evaluating GLP-1 Platforms
When evaluating any GLP-1 telehealth provider from a safety perspective, consider the following: Does the intake process screen for thyroid cancer family history and other absolute contraindications? Does the provider review your complete medication list for interaction risks? Is there a mechanism for ongoing clinical support — dose adjustments, side effect management, lab monitoring — or does oversight effectively end after the initial prescription? What are the credentials of the compounding pharmacy, and do they publish testing data? What is the platform's regulatory compliance history, and have they received any FDA enforcement actions?
If you're experiencing side effects from a current GLP-1 regimen and aren't getting adequate provider support, our article on troubleshooting GLP-1 therapy that isn't working covers the specific clinical variables to evaluate. And for the science behind how these medications work at the hormonal level — which informs why certain side effects occur — see our GLP-1 weight loss science explainer.
Patients who are also evaluating telehealth platforms for other medication categories may find our analysis of Titan TRT's telehealth model useful for understanding how similar safety evaluation frameworks apply across different treatment categories.
MedicalFoundationOfNC.org Editorial Team — This article is for informational purposes only and does not constitute medical advice. All safety information reflects publicly available clinical data and FDA labeling as of April 2026. Consult a qualified healthcare professional before starting, stopping, or modifying any medication. If you purchase through any links in this article, a commission may be earned at no additional cost to you.